Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges
Guilllermo Castaño-perez, Sara Isabel Castaño-ocampo
Pharmaceutical science. August 27, 2025 DOI: 10.5772/intechopen.1011560 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Psilocybin MDMA LSD ayahuasca |
| Key findings | Psychedelic substances such as psilocybin and MDMA show efficacy in treating certain mental disorders and addictions, with psilocybin effective for treatment-resistant depression, cancer-associated anxiety, alcohol use disorder, and nicotine dependence, and MDMA combined with psychotherapy promising for PTSD. |
Abstract
The resurgence of research on the use of psychedelic substances for the treatment of mental disorders and addictions has generated significant interest in the scientific and clinical communities. This chapter examines the current evidence on the efficacy, safety, and limitations of psychedelics in the treatment of these conditions. Studies investigating the use of psychedelics as monotherapy and in combination with assisted therapies are reviewed, highlighting the potential of substances such as psilocybin, MDMA, LSD, and ayahuasca. In the treatment of mental disorders, psilocybin has shown efficacy in treatment-resistant depression and cancer-associated anxiety, while MDMA combined with psychotherapy shows promise for post-traumatic stress disorder (PTSD). In the field of addictions, psilocybin has been shown to be effective for alcohol use disorder and nicotine dependence, and ayahuasca shows potential in the treatment of various substance use disorders.